• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

VIRMA 的过表达通过依赖 mA 的未折叠蛋白反应调节赋予乳腺癌易感性。

Overexpression of VIRMA confers vulnerability to breast cancers via the mA-dependent regulation of unfolded protein response.

机构信息

Epigenetics and RNA Biology Program Centenary Institute, The University of Sydney, Camperdown, NSW, 2006, Australia.

Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW, 2006, Australia.

出版信息

Cell Mol Life Sci. 2023 May 19;80(6):157. doi: 10.1007/s00018-023-04799-4.

DOI:10.1007/s00018-023-04799-4
PMID:37208522
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10198946/
Abstract

Virilizer-like mA methyltransferase-associated protein (VIRMA) maintains the stability of the mA writer complex. Although VIRMA is critical for RNA mA deposition, the impact of aberrant VIRMA expression in human diseases remains unclear. We show that VIRMA is amplified and overexpressed in 15-20% of breast cancers. Of the two known VIRMA isoforms, the nuclear-enriched full-length but not the cytoplasmic-localised N-terminal VIRMA promotes mA-dependent breast tumourigenesis in vitro and in vivo. Mechanistically, we reveal that VIRMA overexpression upregulates the mA-modified long non-coding RNA, NEAT1, which contributes to breast cancer cell growth. We also show that VIRMA overexpression enriches mA on transcripts that regulate the unfolded protein response (UPR) pathway but does not promote their translation to activate the UPR under optimal growth conditions. Under stressful conditions that are often present in tumour microenvironments, VIRMA-overexpressing cells display enhanced UPR and increased susceptibility to death. Our study identifies oncogenic VIRMA overexpression as a vulnerability that may be exploited for cancer therapy.

摘要

VIRMA 样 mA 甲基转移酶相关蛋白 (VIRMA) 维持 mA 书写复合物的稳定性。尽管 VIRMA 对 RNA mA 沉积至关重要,但异常 VIRMA 表达在人类疾病中的影响尚不清楚。我们表明,VIRMA 在 15-20%的乳腺癌中扩增和过表达。在两种已知的 VIRMA 异构体中,富含核的全长而非细胞质定位的 N 端 VIRMA 促进体外和体内 mA 依赖性乳腺癌发生。在机制上,我们揭示了 VIRMA 过表达上调 mA 修饰的长非编码 RNA NEAT1,这有助于乳腺癌细胞生长。我们还表明,VIRMA 过表达会使调节未折叠蛋白反应 (UPR) 途径的转录本上的 mA 富集,但在最佳生长条件下不会促进其翻译以激活 UPR。在肿瘤微环境中经常存在的应激条件下,过表达 VIRMA 的细胞显示出增强的 UPR 和对死亡的敏感性增加。我们的研究确定致癌 VIRMA 过表达是一种脆弱性,可能被用于癌症治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/d9275ca0612e/18_2023_4799_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/5ded616887ec/18_2023_4799_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/40fc688e0dd1/18_2023_4799_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/628a6003d50a/18_2023_4799_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/29637f697ec7/18_2023_4799_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/069ccc795b0d/18_2023_4799_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/2017784a5b9d/18_2023_4799_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/d9275ca0612e/18_2023_4799_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/5ded616887ec/18_2023_4799_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/40fc688e0dd1/18_2023_4799_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/628a6003d50a/18_2023_4799_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/29637f697ec7/18_2023_4799_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/069ccc795b0d/18_2023_4799_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/2017784a5b9d/18_2023_4799_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a149/11072000/d9275ca0612e/18_2023_4799_Fig7_HTML.jpg

相似文献

1
Overexpression of VIRMA confers vulnerability to breast cancers via the mA-dependent regulation of unfolded protein response.VIRMA 的过表达通过依赖 mA 的未折叠蛋白反应调节赋予乳腺癌易感性。
Cell Mol Life Sci. 2023 May 19;80(6):157. doi: 10.1007/s00018-023-04799-4.
2
VIRMA-Dependent N6-Methyladenosine Modifications Regulate the Expression of Long Non-Coding RNAs CCAT1 and CCAT2 in Prostate Cancer.VIRMA 依赖性 N6-甲基腺苷修饰调控前列腺癌中长链非编码 RNA CCAT1 和 CCAT2 的表达。
Cancers (Basel). 2020 Mar 25;12(4):771. doi: 10.3390/cancers12040771.
3
VIRMA Facilitates Triple-Negative Breast Cancer Progression via Increasing m6A-Dependent KIF15 Expression.VIRMA 通过增加 m6A 依赖性 KIF15 表达促进三阴性乳腺癌进展。
Discov Med. 2023 Oct;35(178):787-795. doi: 10.24976/Discov.Med.202335178.73.
4
KIAA1429/VIRMA promotes breast cancer progression by m A-dependent cytosolic HAS2 stabilization.KIAA1429/VIRMA 通过 mA 依赖性胞质 HAS2 稳定促进乳腺癌进展。
EMBO Rep. 2023 Oct 9;24(10):e55506. doi: 10.15252/embr.202255506. Epub 2023 Sep 14.
5
Role of m6A methyltransferase component VIRMA in multiple human cancers (Review).m6A甲基转移酶组分VIRMA在多种人类癌症中的作用(综述)
Cancer Cell Int. 2021 Mar 17;21(1):172. doi: 10.1186/s12935-021-01868-1.
6
VIRMA contributes to non-small cell lung cancer progression via N-methyladenosine-dependent DAPK3 post-transcriptional modification.VIRMA 通过 N6-甲基腺苷依赖的 DAPK3 转录后修饰促进非小细胞肺癌进展。
Cancer Lett. 2021 Dec 1;522:142-154. doi: 10.1016/j.canlet.2021.08.027. Epub 2021 Sep 11.
7
VIRMA promotes nasopharyngeal carcinoma, tumorigenesis, and metastasis by upregulation of E2F7 in an m6A-dependent manner.VIRMA 通过依赖 m6A 的方式上调 E2F7 促进鼻咽癌的发生、肿瘤发生和转移。
J Biol Chem. 2023 May;299(5):104677. doi: 10.1016/j.jbc.2023.104677. Epub 2023 Apr 5.
8
The component of the mA writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors.mA 写入复合物 VIRMA 的组成部分与生殖细胞肿瘤中的侵袭性肿瘤表型、DNA 损伤反应和顺铂耐药性有关。
J Exp Clin Cancer Res. 2021 Aug 25;40(1):268. doi: 10.1186/s13046-021-02072-9.
9
mA RNA modification and its writer/reader VIRMA/YTHDF3 in testicular germ cell tumors: a role in seminoma phenotype maintenance.mA RNA 修饰及其作者/读者 VIRMA/YTHDF3 在睾丸生殖细胞肿瘤中的作用:在精原细胞瘤表型维持中的作用。
J Transl Med. 2019 Mar 12;17(1):79. doi: 10.1186/s12967-019-1837-z.
10
Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer.未折叠蛋白反应的预期性雌激素激活与雌激素受体α阳性乳腺癌的细胞增殖及不良预后相关。
Oncogene. 2015 Jul;34(29):3760-9. doi: 10.1038/onc.2014.292. Epub 2014 Sep 29.

引用本文的文献

1
The Multifaceted Role of VIRMA, a Core Component of the Methyltransferase Complex, in Cancer and Cancer Therapy.VIRMA(甲基转移酶复合物的核心成分)在癌症及癌症治疗中的多方面作用
Biomolecules. 2025 Jun 22;15(7):912. doi: 10.3390/biom15070912.
2
Genetically Encoded Trensor Circuits Report HeLa Cell Treatment with Polyplexed Plasmid DNA and Small-Molecule Transfection Modulators.基因编码的张力环电路报告 HeLa 细胞用多聚体化质粒 DNA 和小分子转染调节剂处理的情况。
ACS Synth Biol. 2024 Oct 18;13(10):3163-3172. doi: 10.1021/acssynbio.4c00148. Epub 2024 Sep 6.
3
N-methyladenosine (mA) RNA modification in chronic myeloid leukemia: unveiling a novel therapeutic target.

本文引用的文献

1
mA methyltransferase KIAA1429 acts as an oncogenic factor in colorectal cancer by regulating SIRT1 in an mA-dependent manner.mA甲基转移酶KIAA1429通过以mA依赖的方式调节SIRT1,在结直肠癌中作为一种致癌因子发挥作用。
Cell Death Discov. 2022 Feb 25;8(1):83. doi: 10.1038/s41420-022-00878-w.
2
Downregulation of the FTO mA RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors.FTO mA RNA 去甲基酶下调促进上皮性肿瘤 EMT 介导的进展和对 Wnt 抑制剂的敏感性。
Nat Cancer. 2021 Jun;2(6):611-628. doi: 10.1038/s43018-021-00223-7. Epub 2021 Jun 23.
3
SMC1A regulated by KIAA1429 in m6A-independent manner promotes EMT progress in breast cancer.
N6-甲基腺苷(m6A)RNA 修饰在慢性髓系白血病中的作用:揭示一个新的治疗靶点。
Cell Mol Life Sci. 2024 Jul 31;81(1):326. doi: 10.1007/s00018-024-05379-w.
4
Dynamic changes in RNA mA and 5 hmC influence gene expression programs during macrophage differentiation and polarisation.RNA mA 和 5hmC 的动态变化影响巨噬细胞分化和极化过程中的基因表达程序。
Cell Mol Life Sci. 2024 May 23;81(1):229. doi: 10.1007/s00018-024-05261-9.
5
A multiomics dataset for the study of RNA modifications in human macrophage differentiation and polarisation.用于研究人巨噬细胞分化和极化中 RNA 修饰的多组学数据集。
Sci Data. 2024 Feb 28;11(1):252. doi: 10.1038/s41597-024-03076-8.
6
Recent advances of m6A methylation in skeletal system disease.m6A 甲基化在骨骼系统疾病中的最新进展。
J Transl Med. 2024 Feb 14;22(1):153. doi: 10.1186/s12967-024-04944-y.
由KIAA1429以不依赖于m6A的方式调控的SMC1A促进乳腺癌的上皮-间质转化进程。
Mol Ther Nucleic Acids. 2021 Aug 19;27:133-146. doi: 10.1016/j.omtn.2021.08.009. eCollection 2022 Mar 8.
4
NEAT1 is essential for metabolic changes that promote breast cancer growth and metastasis.NEAT1 对于促进乳腺癌生长和转移的代谢变化是必不可少的。
Cell Metab. 2021 Dec 7;33(12):2380-2397.e9. doi: 10.1016/j.cmet.2021.11.011.
5
KIAA1429 is a potential prognostic marker in colorectal cancer by promoting the proliferation via downregulating WEE1 expression in an m6A-independent manner.KIAA1429 通过以 m6A 非依赖方式下调 WEE1 表达促进增殖,成为结直肠癌的一个潜在预后标志物。
Oncogene. 2022 Jan;41(5):692-703. doi: 10.1038/s41388-021-02066-z. Epub 2021 Nov 24.
6
VIRMA contributes to non-small cell lung cancer progression via N-methyladenosine-dependent DAPK3 post-transcriptional modification.VIRMA 通过 N6-甲基腺苷依赖的 DAPK3 转录后修饰促进非小细胞肺癌进展。
Cancer Lett. 2021 Dec 1;522:142-154. doi: 10.1016/j.canlet.2021.08.027. Epub 2021 Sep 11.
7
mA RNA methylation regulates promoter- proximal pausing of RNA polymerase II.m⁶A 甲基化调控 RNA 聚合酶 II 的启动子近端暂停。
Mol Cell. 2021 Aug 19;81(16):3356-3367.e6. doi: 10.1016/j.molcel.2021.06.023. Epub 2021 Jul 22.
8
Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer.YTHDF2 的抑制会触发 MYC 驱动型乳腺癌中的蛋白毒性细胞死亡。
Mol Cell. 2021 Aug 5;81(15):3048-3064.e9. doi: 10.1016/j.molcel.2021.06.014. Epub 2021 Jul 2.
9
A Cell Culture Model that Mimics Physiological Tissue Oxygenation Using Oxygen-permeable Membranes.一种使用透氧膜模拟生理组织氧合的细胞培养模型。
Bio Protoc. 2019 Sep 20;9(18):e3371. doi: 10.21769/BioProtoc.3371.
10
RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming.RNA m6A 甲基化通过巨噬细胞重编程调控癌症生长和转移。
Nat Commun. 2021 Mar 2;12(1):1394. doi: 10.1038/s41467-021-21514-8.